Quince Therapeutics (NASDAQ:QNCX) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Quince Therapeutics (NASDAQ:QNCX) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Other research analysts also recently issued reports about the company. Weiss Ratings upgraded Quince Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 12th. Leerink Partners started coverage on shares of Quince Therapeutics in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $80.00 price target on the stock. Oppenheimer started coverage on Quince Therapeutics in a research report on Wednesday, July 29th. They issued an “outperform” rating and a $82.00 target price on the stock. Craig Hallum assumed coverage on Quince Therapeutics in a research note on Thursday. They set a “buy” rating and a $68.00 target price on the stock. Finally, Lifesci Capital raised Quince Therapeutics to a “strong-buy” rating in a report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $260.00.

Quince Therapeutics Price Performance

NASDAQ:QNCX opened at $33.93 on Friday. Quince Therapeutics has a fifty-two week low of $15.10 and a fifty-two week high of $909.98. The stock has a market capitalization of $34.61 million, a PE ratio of -0.22 and a beta of 1.36. The business’s 50-day simple moving average is $22.45 and its 200-day simple moving average is $24.99.

Quince Therapeutics (NASDAQ:QNCX) last announced its earnings results on Friday, August 14th. The company reported ($12.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($28.02) by $15.71.

Institutional Trading of Quince Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of QNCX. BlackRock Inc. acquired a new stake in Quince Therapeutics in the 2nd quarter worth about $31,000. XTX Topco Ltd bought a new position in shares of Quince Therapeutics during the second quarter worth approximately $37,000. Intellectus Partners LLC bought a new position in shares of Quince Therapeutics during the fourth quarter worth approximately $179,000. Bridgeway Capital Management LLC raised its position in shares of Quince Therapeutics by 20.9% in the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after buying an additional 22,200 shares in the last quarter. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of Quince Therapeutics in the fourth quarter valued at approximately $213,000. Institutional investors and hedge funds own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.